Doptive cancer immunotherapy: Discovering the best targets

Journal of Molecular Medicine

Volumn 80, Issue 4, 2002, Pages 212-218

  Perreault, Claude ^a   Brochu, Sylvie ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Cytotoxic T lymphocyte; Graft versus host disease; Major histocompatibility complex; Minor histocompatibility antigen; Tumor immunity

Indexed keywords

EPITOPE; FAS LIGAND; GAMMA INTERFERON; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MINOR HISTOCOMPATIBILITY ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHIMERA; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE SYSTEM; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; T LYMPHOCYTE; ADOPTIVE TRANSFER; GRAFT REJECTION; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM;

ADOPTIVE TRANSFER; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS TUMOR EFFECT; HOST VS GRAFT REACTION; HUMANS; IMMUNOTHERAPY; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASMS; T-LYMPHOCYTES;

EID: 0036010948     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-001-0315-1     Document Type: Review

References (87)

1. Regulation of the immune response by antigen
2. Proteolysis in MHC class II antigen presentation: Who's in charge?
3. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
4. MHC class I molecules can direct proteolytic cleavage of antigenic precursors in the endoplasmic reticulum
5. Innate immunity: The virtues of a nonclonal system of recognition
6. Natural adjuvants: Endogenous activators of dendritic cells
7. + T cell effector mechanisms in resistance to infection
8. + T-cell memory
9. Human tumor antigens recognized by T lymphocytes
10. Progress in human tumour immunology and immunotherapy
11. T cell defined tumor antigens
12. Cancer immunotherapy: Synthetic and natural peptides in the balance
13. + cancers
14. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
15. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
16. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
17. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
18. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
19. TAP expression provides a general method for improving the recognition of malignant cells in vivo
20. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow
21. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
22. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice
23. The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses
24. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue
25. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo
26. + melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy
27. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
28. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
29. Identification of classical minor histocompatibility antigen as cell-derived peptide
30. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y
31. Minor histocompatibility antigens
32. Graft-versus-leukemia reactions after bone marrow transplantation
33. Haematopoietic cell transplantation as immunotherapy
34. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
35. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
36. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
37. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation
38. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
39. Identical-twin bone marrow transplants for leukemia
40. The non-MHC transplantation antigens: Neither weak nor minor
41. Minor histocompatibility antigens
42. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions
43. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire
44. Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: The H60 histocompatibility antigen dominates over all others
45. Graft-versus-leukemia in the rat-the antileukemic efficacy of syngeneic and allogeneic graft-versus-host disease
46. Graft-versus-leukemia in rat MHC-mismatched bone marrow transplantation is merely an allogeneic effect
47. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
48. Immunodominant minor histocompatibility antigens: The major ones
49. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing
50. Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy
51. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens
52. Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease
53. Shaping the repertoire of cytotoxic T-lymphocyte responses: Explanation for the immunodominance effect whereby cytotoxic T lymphocytes specific for immunodominant antigens prevent recognition of nondominant antigens
54. dom1) encoded by the classical H7 minor histocompatibility locus
55. Adoptive transfer of T lymphocytes targeted to a single immunodominant minor histocompatibility antigen eradicates leukemia cells without causing graft-versus-host disease
56. Cytokine cascades in acute graft-versus-host disease
57. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading
58. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts
59. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope
60. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
61. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system- restricted minor histocompatibility antigens
62. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using den-dritic cells and HLA-tetramers
63. Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs.-host disease
64. Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-αβ
65. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
66. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
67. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma
68. The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism
69. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation
70. Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression
71. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses
72. Immunodomination results from functional differences between competing CTL
73. Alloreactivity as a source of high avidity peptide-specific human CTL
74. Characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection
75. Crystal structure of a T cell receptor bound to an allogeneic MHC molecule
76. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy
77. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules
78. + progenitor cells by cytotoxic T lymphocytes specific for WT1
79. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
80. Deletion of high-avidity T cells by thymic epithelium
81. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-γmechanisms that cannot be predicted from in vitro T cell characteristics
82. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: Factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors
83. Immunotherapy of melanoma: A dichotomy in the requirement for IFN-γ in vaccine-induced antitumor immunity versus adoptive immunotherapy
84. Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses
85. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation
86. + natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production